Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.
|Original language||English (US)|
|Title of host publication||Treatment-Refractory Schizophrenia|
|Subtitle of host publication||A Clinical Conundrum|
|Publisher||Springer Berlin Heidelberg|
|Number of pages||20|
|Publication status||Published - Jan 1 2014|
ASJC Scopus subject areas